Positive Data for Istaroxime in Early Cardiogenic Shock
Brings Notable Interest from Potential Partners
WARRINGTON, Pa., June 29, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM:WINT), a biotechnology company focused on advancing late-stage interventions for acute cardiovascular disorders, today provided an update to its strategy and pursuit related to partnerships and transactions.
Read more at globenewswire.com